m6A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy is a research paper published in The EMBO Journal (2020). On theSindex it has a DataRank of 5.1. It has been cited 422 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.907
From this paper's citation signal
Citation Network Contribution
4.2
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institutes of Health SIG
Grant: S10 OD026929
National Institutes of Health
Grant: DA046171
National Cancer Institute
Grant: CA177322
HHS|NIH|National Institute on Drug Abuse
Grant: DA039562
HHS|NIH|National Institute of Allergy and Infectious Diseases
Grant: AI125103
NIDA NIH HHS
Grant: DP1 DA039562
NIDA NIH HHS
Grant: R01 DA046171
NCI NIH HHS
Grant: P01 CA177322
NIAID NIH HHS
Grant: R21 AI125103
National Institutes of Health
Grant: 1R01DA046171-01
Identification and Regulation of RNA Modification by HIV infection and Methamphetamine
National Institutes of Health
Grant: 1R21AI125103-01A1
Regulation of HIV-1 Replication by Cellular IncRNAs
National Institutes of Health
Grant: 1S10OD026929-01
Illumina NovaSeq 6000 Sequencing System
National Institutes of Health
Grant: 1DP1DA039562-01
Modeling HIV/AIDS Associated Neurological Disorders with Human Pluripotent Cells
National Institutes of Health
Grant: 5P01CA177322-03
Innate Immune Responses and Vaccines Against Tumor-Associated Herpesviruses
FWCI
18.27
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 1 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 2 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 3 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 2 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 3 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 4 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 4 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 5 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 5 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 6 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 6 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 7 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 7 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 8 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 8 of Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer
Additional file 1 of METTL3-mediated m6A methylation regulates ovarian cancer progression by recruiting myeloid-derived suppressor cells
Additional file 1 of METTL3-mediated m6A methylation regulates ovarian cancer progression by recruiting myeloid-derived suppressor cells
Additional file 19 of Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy
Additional file 19 of Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy